Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Depreciation & Amortization (CF): 2009-2025

Historic Depreciation & Amortization (CF) for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $649,000.

  • Gyre Therapeutics' Depreciation & Amortization (CF) rose 45.84% to $649,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 64.94%. This contributed to the annual value of $1.5 million for FY2024, which is 44.23% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Depreciation & Amortization (CF) of $649,000 as of Q3 2025, which was up 1.25% from $641,000 recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Depreciation & Amortization (CF) peaked at $867,000 during Q4 2022, and registered a low of $40,000 during Q3 2022.
  • In the last 3 years, Gyre Therapeutics' Depreciation & Amortization (CF) had a median value of $415,000 in 2024 and averaged $404,364.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 653.91% in 2022, then tumbled by 65.63% in 2023.
  • Gyre Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $115,000 in 2021, then surged by 653.91% to $867,000 in 2022, then crashed by 65.63% to $298,000 in 2023, then spiked by 54.70% to $461,000 in 2024, then skyrocketed by 45.84% to $649,000 in 2025.
  • Its Depreciation & Amortization (CF) stands at $649,000 for Q3 2025, versus $641,000 for Q2 2025 and $535,000 for Q1 2025.